Pub Date : 2019-05-20DOI: 10.24966/SRDT-2060/S1005
H. Abrahamse
The Effect of Low Intensity Irradiation on Breast Cancer Cells and Breast Cancer Stem Cells. The mechanism by which tumor proliferation, invasiveness and recurrence are sustained in malignant cancer has not been fully elu-cidated. Taking into account the findings of previous researches, one have strong reasons to believe that it might result from a small pop-ulation of cells referred to as Cancer Stem Cells (CSCs). This study aimed to investigate and compare the photobiomodulative effect of Low Intensity Laser Irradiation (LILI) treatment on Breast Cancer Stem Cells (BCSCs) and Breast Cancer Cells (BCCs). BCSCs were isolated from the MCF-7 cell line based on their CD44+ phenotype using magnetic-activated cell sorting. CD44 antigen was detected in BCSCs using fluorescent microscopy. Cellular response to the treatment was evaluated based on their viability, proliferation and toxicity. Positive detection of CD44 confirmed the stemness of isolat ed BCSCs. Treated BCCs and BCSCs showed an increase in their proliferation and viability after being exposed to 5-40 J/cm2 using wavelengths of 636, 825 and 1060 nm. Membrane integrity assay revealed a decrease in cytotoxicity in both BCCs and BCSCs after treatment with low fluences of LILI. This study revealed that LILI did not have a bioinhibitory effect on both cell types.
{"title":"The Effect of Low Intensity Laser Irradiation on Breast Cancer Cells and Breast Cancer Stem Cells","authors":"H. Abrahamse","doi":"10.24966/SRDT-2060/S1005","DOIUrl":"https://doi.org/10.24966/SRDT-2060/S1005","url":null,"abstract":"The Effect of Low Intensity Irradiation on Breast Cancer Cells and Breast Cancer Stem Cells. The mechanism by which tumor proliferation, invasiveness and recurrence are sustained in malignant cancer has not been fully elu-cidated. Taking into account the findings of previous researches, one have strong reasons to believe that it might result from a small pop-ulation of cells referred to as Cancer Stem Cells (CSCs). This study aimed to investigate and compare the photobiomodulative effect of Low Intensity Laser Irradiation (LILI) treatment on Breast Cancer Stem Cells (BCSCs) and Breast Cancer Cells (BCCs). BCSCs were isolated from the MCF-7 cell line based on their CD44+ phenotype using magnetic-activated cell sorting. CD44 antigen was detected in BCSCs using fluorescent microscopy. Cellular response to the treatment was evaluated based on their viability, proliferation and toxicity. Positive detection of CD44 confirmed the stemness of isolat ed BCSCs. Treated BCCs and BCSCs showed an increase in their proliferation and viability after being exposed to 5-40 J/cm2 using wavelengths of 636, 825 and 1060 nm. Membrane integrity assay revealed a decrease in cytotoxicity in both BCCs and BCSCs after treatment with low fluences of LILI. This study revealed that LILI did not have a bioinhibitory effect on both cell types.","PeriodicalId":93004,"journal":{"name":"HSOA journal of stem cells research, development & therapy","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89203714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-10DOI: 10.24966/SRDT-2060/S1001
K. Pettine, Paisley Laboratories
{"title":"The Biologic Treatment of Osteoarthritis with Mesenchymal Stem Cell Exosomes: The Future is Now","authors":"K. Pettine, Paisley Laboratories","doi":"10.24966/SRDT-2060/S1001","DOIUrl":"https://doi.org/10.24966/SRDT-2060/S1001","url":null,"abstract":"","PeriodicalId":93004,"journal":{"name":"HSOA journal of stem cells research, development & therapy","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77156000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-10DOI: 10.24966/SRDT-2060/S1004
Suruchi Garg
{"title":"Research Article Use of Stem Cells in Intervention Dermatology and Trichology: A New Hope","authors":"Suruchi Garg","doi":"10.24966/SRDT-2060/S1004","DOIUrl":"https://doi.org/10.24966/SRDT-2060/S1004","url":null,"abstract":"","PeriodicalId":93004,"journal":{"name":"HSOA journal of stem cells research, development & therapy","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89920509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01Epub Date: 2019-11-06DOI: 10.24966/srdt-2060/100019
Hang-Soo Park, Dalia Ashour, Amro Elsharoud, Rishi Man Chugh, Nahed Ismail, Abdeljabar El Andaloussi, Ayman Al-Hendy
Primary Ovarian Insufficiency (POI) refers to an ovarian loss of function in women under the age of 40. Unfortunately, currently, there is no effective treatment available for POI-related infertility. Alternatives such as the use of egg donations are culturally and ethically unacceptable to many couples. Human Bone marrow-derived Mesenchymal Stem Cells (MSCs) are known for their ability to differentiate into other cell types, once primed by the organ microenvironment. Importantly MSCs produce a vast array of bioactive factors many of them have been shown to enhance neovascularization in various tissues. Recently, preliminary data from our ongoing clinical trial revealed encouraging preliminary data after autologous MSC engraftment into the ovaries of 2 POI patients with durable elevation in serum estrogen levels and increase in size of treated ovaries sustained up to one-year post cell therapy. In this study, we investigated the action of the mechanisms of MSCs treatment on a POI ovary. We designed an in vitro study using MSC secretome and Human Ovarian Endothelial Cells (HOVECs) to understand the molecular mechanisms by which MSC mediates their angiogenic properties and regenerative effects. Human primary HOVECs were treatment with MSC secretome and examined by FACS for the expression of angiogenesis markers such as Endoglin, Tie-2, and VEGF. The formation of vessels was evaluated by using a 3D Matrigel tubulogenesis assay. We observed that the expression of proliferation marker Ki67 was significantly increased under treatment with MSC secretome in HOVEC cells (P4). MSCs secretome treatment also induced significantly higher expression of several angiogenic markers such as VEGFR2, Tie2/Tek, VE-Cadherin, Endoglin, and VEGF compared to matched control (P4). Furthermore, MSC secretome significantly increased the number of branching points in tubulogenesis assay (P4). Our study suggests that MSC secretome likely contains bioactive factors that can enhance ovarian angiogenesis. Further characterization of these factors can lead to novel therapeutic options for women with premature ovarian insufficiency and other related causes of female infertility.
{"title":"Towards Cell free Therapy of Premature Ovarian Insufficiency: Human Bone Marrow Mesenchymal Stem Cells Secretome Enhances Angiogenesis in Human Ovarian Microvascular Endothelial Cells.","authors":"Hang-Soo Park, Dalia Ashour, Amro Elsharoud, Rishi Man Chugh, Nahed Ismail, Abdeljabar El Andaloussi, Ayman Al-Hendy","doi":"10.24966/srdt-2060/100019","DOIUrl":"https://doi.org/10.24966/srdt-2060/100019","url":null,"abstract":"<p><p>Primary Ovarian Insufficiency (POI) refers to an ovarian loss of function in women under the age of 40. Unfortunately, currently, there is no effective treatment available for POI-related infertility. Alternatives such as the use of egg donations are culturally and ethically unacceptable to many couples. Human Bone marrow-derived Mesenchymal Stem Cells (MSCs) are known for their ability to differentiate into other cell types, once primed by the organ microenvironment. Importantly MSCs produce a vast array of bioactive factors many of them have been shown to enhance neovascularization in various tissues. Recently, preliminary data from our ongoing clinical trial revealed encouraging preliminary data after autologous MSC engraftment into the ovaries of 2 POI patients with durable elevation in serum estrogen levels and increase in size of treated ovaries sustained up to one-year post cell therapy. In this study, we investigated the action of the mechanisms of MSCs treatment on a POI ovary. We designed an in vitro study using MSC secretome and Human Ovarian Endothelial Cells (HOVECs) to understand the molecular mechanisms by which MSC mediates their angiogenic properties and regenerative effects. Human primary HOVECs were treatment with MSC secretome and examined by FACS for the expression of angiogenesis markers such as Endoglin, Tie-2, and VEGF. The formation of vessels was evaluated by using a 3D Matrigel tubulogenesis assay. We observed that the expression of proliferation marker Ki67 was significantly increased under treatment with MSC secretome in HOVEC cells (P4). MSCs secretome treatment also induced significantly higher expression of several angiogenic markers such as VEGFR2, Tie2/Tek, VE-Cadherin, Endoglin, and VEGF compared to matched control (P4). Furthermore, MSC secretome significantly increased the number of branching points in tubulogenesis assay (P4). Our study suggests that MSC secretome likely contains bioactive factors that can enhance ovarian angiogenesis. Further characterization of these factors can lead to novel therapeutic options for women with premature ovarian insufficiency and other related causes of female infertility.</p>","PeriodicalId":93004,"journal":{"name":"HSOA journal of stem cells research, development & therapy","volume":"5 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38006340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-19DOI: 10.24966/srdt-2060/100011
Elliot B. Lander
The fascinating story of Stromal Vascular Fraction (SVF) and its prominent role in autologous regenerative therapies (or Personal Cell Therapy PCT) continues to evolve as scientific and regulatory issues develop. The primary objective of this special report will elucidate the history, composition and scientific analysis of SVF as an autologous biologic experiencing widespread clinical use. SVF has several distinct features that prevent it from ever being manufactured as a mass produced pharmaceutical and distributed for clinical use. Autologous SVF contains a unique mixture of 4 different types of autologous stem cells in an extremely rich cytokine milieu. It is intended to be used fresh and at point of care obviating its use in commercialization. It is personalized with the patient’s own DNA, and it contains the patient’s own biologic profile of possible measurable or unmeasurable communicable diseases. Other stem cell products being developed as drugs under research and development differ from autologous SVF as they generally contain doses of a single cell types that may or may not be autologous. Personal Cell Therapy using autologous biologic products should be protected from overbearing regulation with its use supported by clinical trials helping us to learn more about its regenerative potential. Laboratory investigations can then optimally help optimize areas that need further support.
{"title":"Autologous Stromal Vascular Fraction: A New Era of Personal Cell Therapy","authors":"Elliot B. Lander","doi":"10.24966/srdt-2060/100011","DOIUrl":"https://doi.org/10.24966/srdt-2060/100011","url":null,"abstract":"The fascinating story of Stromal Vascular Fraction (SVF) and its prominent role in autologous regenerative therapies (or Personal Cell Therapy PCT) continues to evolve as scientific and regulatory issues develop. The primary objective of this special report will elucidate the history, composition and scientific analysis of SVF as an autologous biologic experiencing widespread clinical use. SVF has several distinct features that prevent it from ever being manufactured as a mass produced pharmaceutical and distributed for clinical use. Autologous SVF contains a unique mixture of 4 different types of autologous stem cells in an extremely rich cytokine milieu. It is intended to be used fresh and at point of care obviating its use in commercialization. It is personalized with the patient’s own DNA, and it contains the patient’s own biologic profile of possible measurable or unmeasurable communicable diseases. Other stem cell products being developed as drugs under research and development differ from autologous SVF as they generally contain doses of a single cell types that may or may not be autologous. Personal Cell Therapy using autologous biologic products should be protected from overbearing regulation with its use supported by clinical trials helping us to learn more about its regenerative potential. Laboratory investigations can then optimally help optimize areas that need further support.","PeriodicalId":93004,"journal":{"name":"HSOA journal of stem cells research, development & therapy","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88024991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-19DOI: 10.24966/SRDT-2060/100010
Fernández Viña Matías, Cardiology San Nicolas Clinic
{"title":"Autologous Adult Bone Marrow Total Nucleated Cells for Chronic Heart Failure - 2 Cases Report: 1 Year Follow Up","authors":"Fernández Viña Matías, Cardiology San Nicolas Clinic","doi":"10.24966/SRDT-2060/100010","DOIUrl":"https://doi.org/10.24966/SRDT-2060/100010","url":null,"abstract":"","PeriodicalId":93004,"journal":{"name":"HSOA journal of stem cells research, development & therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89119193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：